

AMENDMENT: IN THE SPECIFICATION

Please enter the Sequence Listing into the application.

1. Please replace the paragraph [0025] with the following amended paragraph(s):

[0025] **Figure 4:** A. Sequence alignment of M2-1 N-terminal mutants, showing the residues that were changed from PVM to RSV for each PR M2-1 mutant PR1-PR19. A2, residues 1-30 of SEQ ID NO:19; PVM, residues 1-29 of SEQ ID NO:20; PR1, SEQ ID NO:21; PR2, SEQ ID NO:22; PR3, SEQ ID NO:23; PR4, SEQ ID NO:24; PR5, SEQ ID NO:25; PR6, SEQ ID NO:26; PR7, SEQ ID NO:27; PR8, SEQ ID NO:28; PR9, SEQ ID NO:29; PR10, SEQ ID NO:30; PR11, SEQ ID NO:31; PR12, SEQ ID NO:32; PR13, SEQ ID NO:33; PR14, SEQ ID NO:34; PR15, SEQ ID NO:35; PR16, SEQ ID NO:36; PR17, SEQ ID NO:37; PR18, SEQ ID NO:38; PR19, SEQ ID NO:39. B. Bar graph illustrating relative activity in an RSV lacZ minigenome assay; the level of β -galactosidase expressed by each mutant is normalized to RSV M2-1.

2. Please replace the paragraph [0026] with the following amended paragraph(s):

[0026] **Figure 5:** A. Sequence alignment of M2-1 N-terminal mutants, showing the residues that were changed from RSV to PVM for each RSV M2-1 mutant RS1-RS11. PVM, residues 1-29 of SEQ ID NO:20; A2, residues 1-30 of SEQ ID NO:19; RS1, SEQ ID NO:40; RS2, SEQ ID NO:41; RS3, SEQ ID NO:42; RS4, SEQ ID NO:43; RS5, SEQ ID NO:44; RS6, SEQ ID NO:45; RS7, SEQ ID NO:46; RS8, SEQ ID NO:47; RS9, SEQ ID NO:48; RS10, SEQ ID NO:49; RS11, SEQ ID NO:50. B. Bar graph illustrating relative activity of M2-1 mutants; the level of β -galactosidase expressed by each mutant is normalized to wt RSV M2-1.

3. Please replace the paragraph [0035] with the following amended paragraph(s):

[0035] **Figure 14:** Sequence alignment of P proteins in the central region (aa# 106-121) and in the C terminal region (aa# 226-241). The serine residues in these regions are underlined. P proteins illustrated are the P proteins from: RSV-A2, human RSV subgroup A2 strain (central,

SEQ ID NO:54; C-terminal, SEQ ID NO:55); Long, human RSV subgroup A long strain (central, SEQ ID NO:56; C-terminal, SEQ ID NO:57); B18537, Human RSV subgroup B strain 18537_(central, SEQ ID NO:58; C-terminal, SEQ ID NO:59); MPV, human metapneumovirus (central, SEQ ID NO:60; C-terminal, SEQ ID NO:61); Bovine, bovine RSV_(central, SEQ ID NO:62; C-terminal, SEQ ID NO:63); Avian, avian Pneumovirus_(central, SEQ ID NO:64; C-terminal, SEQ ID NO:65); and Ovine, ovine RSV_(central, SEQ ID NO:66; C-terminal, SEQ ID NO:67). P protein mutants Mut1-Mut6 are also depicted. Mut1 (central, SEQ ID NO:68; C-terminal, SEQ ID NO:69), Mut2 (central, SEQ ID NO:70; C-terminal, SEQ ID NO:71), Mut3 (central, SEQ ID NO:72; C-terminal, SEQ ID NO:73), Mut4 (central, SEQ ID NO:74; C-terminal, SEQ ID NO:75), Mut5 (central, SEQ ID NO:76; C-terminal, SEQ ID NO:77), Mut6 (central, SEQ ID NO:78; C-terminal, SEQ ID NO:79).

These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter or agreement with any objection or rejection of record.